Baidu
map
PHARMACOGEN PERS MED 润色咨询

Pharmacogenomics & Personalized Medicine

出版年份：暂无数据 年文章数：505 投稿命中率： 开通期刊会员，数据随心看

出版周期：暂无数据 自引率：暂无数据 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2107395, encodeId=014e210e39590, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤学;药理学<br>经验分享：还不错的一次投稿，编辑比较耐心, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48674781512, createdName=fangyeying2010, createdTime=Sun Dec 25 11:59:02 CST 2022, time=2022-12-25, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1227087, encodeId=cf70122e087b5, content=审稿速度:1.0 | 投稿命中率:5.0<br>经验分享：已投，被拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220703/ac30326af85e40a198bd59fb829e58e1/640aec889c7a46399361ab5ac03a87e9.jpg, createdBy=720f2366630, createdName=Liu～, createdTime=Fri Jun 17 20:35:56 CST 2022, time=2022-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1112731, encodeId=13221112e31b9, content=关键词能否从题目中提炼？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Wed Dec 29 14:52:54 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1112732, encodeId=eaee1112e32e0, content=审稿人会不会通过我提供的关键词检索创新性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:54 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=927050, encodeId=5b3192e05015, content=审稿很快，一审大约3周，2个审稿人提了十多个问题，还好都能回答，返修后1周接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea855439583, createdName=ms6000001223320471, createdTime=Thu Feb 25 10:28:20 CST 2021, time=2021-02-25, status=1, ipAttribution=)]
    2022-12-25 fangyeying2010 来自广西

    审稿速度:6.0 | 投稿命中率:50.0
    偏重的研究方向：肿瘤学;药理学
    经验分享：还不错的一次投稿，编辑比较耐心

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2107395, encodeId=014e210e39590, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤学;药理学<br>经验分享：还不错的一次投稿，编辑比较耐心, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48674781512, createdName=fangyeying2010, createdTime=Sun Dec 25 11:59:02 CST 2022, time=2022-12-25, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1227087, encodeId=cf70122e087b5, content=审稿速度:1.0 | 投稿命中率:5.0<br>经验分享：已投，被拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220703/ac30326af85e40a198bd59fb829e58e1/640aec889c7a46399361ab5ac03a87e9.jpg, createdBy=720f2366630, createdName=Liu～, createdTime=Fri Jun 17 20:35:56 CST 2022, time=2022-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1112731, encodeId=13221112e31b9, content=关键词能否从题目中提炼？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Wed Dec 29 14:52:54 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1112732, encodeId=eaee1112e32e0, content=审稿人会不会通过我提供的关键词检索创新性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:54 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=927050, encodeId=5b3192e05015, content=审稿很快，一审大约3周，2个审稿人提了十多个问题，还好都能回答，返修后1周接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea855439583, createdName=ms6000001223320471, createdTime=Thu Feb 25 10:28:20 CST 2021, time=2021-02-25, status=1, ipAttribution=)]
    2022-06-17 Liu～

    审稿速度:1.0 | 投稿命中率:5.0
    经验分享：已投，被拒

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2107395, encodeId=014e210e39590, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤学;药理学<br>经验分享：还不错的一次投稿，编辑比较耐心, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48674781512, createdName=fangyeying2010, createdTime=Sun Dec 25 11:59:02 CST 2022, time=2022-12-25, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1227087, encodeId=cf70122e087b5, content=审稿速度:1.0 | 投稿命中率:5.0<br>经验分享：已投，被拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220703/ac30326af85e40a198bd59fb829e58e1/640aec889c7a46399361ab5ac03a87e9.jpg, createdBy=720f2366630, createdName=Liu～, createdTime=Fri Jun 17 20:35:56 CST 2022, time=2022-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1112731, encodeId=13221112e31b9, content=关键词能否从题目中提炼？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Wed Dec 29 14:52:54 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1112732, encodeId=eaee1112e32e0, content=审稿人会不会通过我提供的关键词检索创新性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:54 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=927050, encodeId=5b3192e05015, content=审稿很快，一审大约3周，2个审稿人提了十多个问题，还好都能回答，返修后1周接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea855439583, createdName=ms6000001223320471, createdTime=Thu Feb 25 10:28:20 CST 2021, time=2021-02-25, status=1, ipAttribution=)]
    2021-12-29 rayms

    关键词能否从题目中提炼？

    1

    展开1条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2107395, encodeId=014e210e39590, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤学;药理学<br>经验分享：还不错的一次投稿，编辑比较耐心, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48674781512, createdName=fangyeying2010, createdTime=Sun Dec 25 11:59:02 CST 2022, time=2022-12-25, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1227087, encodeId=cf70122e087b5, content=审稿速度:1.0 | 投稿命中率:5.0<br>经验分享：已投，被拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220703/ac30326af85e40a198bd59fb829e58e1/640aec889c7a46399361ab5ac03a87e9.jpg, createdBy=720f2366630, createdName=Liu～, createdTime=Fri Jun 17 20:35:56 CST 2022, time=2022-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1112731, encodeId=13221112e31b9, content=关键词能否从题目中提炼？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Wed Dec 29 14:52:54 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1112732, encodeId=eaee1112e32e0, content=审稿人会不会通过我提供的关键词检索创新性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:54 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=927050, encodeId=5b3192e05015, content=审稿很快，一审大约3周，2个审稿人提了十多个问题，还好都能回答，返修后1周接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea855439583, createdName=ms6000001223320471, createdTime=Thu Feb 25 10:28:20 CST 2021, time=2021-02-25, status=1, ipAttribution=)]
    2021-12-29 MS68862005

    审稿人会不会通过我提供的关键词检索创新性？

    1

    展开1条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2107395, encodeId=014e210e39590, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤学;药理学<br>经验分享：还不错的一次投稿，编辑比较耐心, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48674781512, createdName=fangyeying2010, createdTime=Sun Dec 25 11:59:02 CST 2022, time=2022-12-25, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1227087, encodeId=cf70122e087b5, content=审稿速度:1.0 | 投稿命中率:5.0<br>经验分享：已投，被拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220703/ac30326af85e40a198bd59fb829e58e1/640aec889c7a46399361ab5ac03a87e9.jpg, createdBy=720f2366630, createdName=Liu～, createdTime=Fri Jun 17 20:35:56 CST 2022, time=2022-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1112731, encodeId=13221112e31b9, content=关键词能否从题目中提炼？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Wed Dec 29 14:52:54 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1112732, encodeId=eaee1112e32e0, content=审稿人会不会通过我提供的关键词检索创新性？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:54 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=927050, encodeId=5b3192e05015, content=审稿很快，一审大约3周，2个审稿人提了十多个问题，还好都能回答，返修后1周接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea855439583, createdName=ms6000001223320471, createdTime=Thu Feb 25 10:28:20 CST 2021, time=2021-02-25, status=1, ipAttribution=)]
    2021-02-25 ms6000001223320471

    审稿很快，一审大约3周，2个审稿人提了十多个问题，还好都能回答，返修后1周接收

    0

共9条页码: 1/1页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分

Baidu
Baidu
map
Baidu
map
Baidu
map